Mental disorders in movement disorders

Current Opinion in Psychiatry

Volumn 11, Issue 3, 1998, Pages 315-319

  Bandmann, Oliver ^a   Oertel, Wolfgang H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; FLUOXETINE; KETAMINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

BASAL GANGLION; DEMENTIA; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROPSYCHOLOGY; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PSYCHOSIS; REVIEW; SHY DRAGER SYNDROME; SIDE EFFECT;

EID: 0031945889     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199805000-00014     Document Type: Review

References (35)

1. Huntington's disease collaborative research group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-983.
2. Lovestone S, Hodgson S, Sham P, Differ A, Levy R. Familial psychiatric presentation of Huntington's disease. J Med Genet 1996; 33:128-131.
3. Weigell-Weber M, Scmid W, Spiegel R. Psychiatric symptoms and CAG expansion in Huntington's disease. Am J Med Genet 1996: 67:53-57.
4. Boo GD, Tibben A, Lanser J, Jennekens-Schinkel A, Hermans J, Maat-Kievit A, Roos R. Early cognitive and motor symptoms in identified carriers of the gene for Huntington's disease. Arch Neural 1997; 54:1353-1357.
5. Gray J, Young A, Barker W, Curtis A, Gibson D. Impaired recognition of • disgust in Huntington's disease gene carriers. Brain 1997; 120:2029-2038. Employing a wide range of neuropsychological tests on patients at risk for HD, a highly selective deficit in the recognition of the facial expression of disgust was detected in HD gene carriers.
6. Jason G, Suchowesky O, Pajurkova E, Graham L, Klimek M, Garber A, Poirier-Heine D. Cognitive manifestations of Huntington's disease in relation to genetic structure and clinical onset. Arch Neurol 1997; 54:1081-1088.
7. Murman D, Girodani B, Mellow A, Johanns J, Little R, Hariharan M. Foster N. Cognitive, behavioural, and motor effects of the NMDA antagonist ketamine in Huntington's disase. Neurology 1997; 49:153-161.
8. van Vugt J, Siesling S, Vergeer M. van der Velde E, Roos R. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63:35-39.
9. Como P, Rubin AJ, O'Brien CF, Lawler K. Hickey C, Rubin AE et al. A controlled, trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997; 12:397-401.
10. Philpott L, Kopyov O. Lee A. Jaques S, Duma C, Caine S, et al. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 1997; 6:203-212.
11. Tandberg E, Larsen J, Aarsland D, Laake K, Cummings J. Risk factors for • depression in Parkinson's disease. Arch Neurol 1997; 54:625-630. Most of the observations of this study favour the hypothesis that depression is a primary consequence of brain dysfunction.
12. Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M, et al. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry 1997; 63:590-596.
13. Pilo L, Ring H, Quinn N, Trimble M. Depression in multiple system atrophy and in idiopathic Parkinson's disease: a pilot comparative study. Biol Psychiatry 1996; 39:803-807.
14. Jimenez-Jimenez F, Orti-Pareja M. Cenesthetic hallucinations in a patient with Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1997; 63:120.
15. Graham J. Grünewald R, Sagar H. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63:434-440.
16. Klein C, Kömpf D. Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson's disease. J Neurol 1997; 244:371-377.
17. Sanchez-Ramos J, Ortoll R, Paulson G. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996; 53: 1265-1268.
18. Leiguarda R, Pramstaller P, Merello M, Starkstein S, Lees A, Marsden CD. •• Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997; 120:75-90. This is the first comparative study investigating apraxia in several different akinetic-rigid syndromes. The strength of this study lies in the comparatively large number of patients analysed (45 for Parkinson's disease, 12 for PSP, 10 for MSA, 12 for neuroleptic-induced parkinsonism) and the assessment of both 'anterior' and 'posterior' ideomotor apraxia. The authors concluded that the apraxia observed in Parkinson's disease and PSP may reflect combined corticostriatal dysfunction with ideomotor apraxia lacking in MSA.
19. Churchyard A, Lees A. The relationship between dementia and direct •• involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997; 49:1570-1576. This is a very interesting clinicopathologic study that correlates Mini-Mental State Examination scores and Diagnostic and Statistical Manual of Mental Disorders, third edition, dementia ratings with the density of Lewy bodies, Lewy neuntes, neurofibrillary tangles, neuritic plaques, gliosis and neurons in the hippocampus and amygdala of 27 patients without Alzheimer's disease changes. Cortical Lewy bodies were examined in the anterior cingulate gyrus. The degree of cognitive impairment was correlated with the density of Lewy neurites in the CA2 hippocampal field, raising the possibility that disruption of the connection between the dentate gyrus, entorhinal cortex, septal nuclei and hypothalamus and the hippocampus contributes to dementia in Parkinson's disease.
20. Holthoff-Detto V, Kessler J, Herholz K, Bönner H, Pietryzk U, Würter M, et al. Functional effects of striatal dysfunction in Parkinson's disease. Arch Neurol 1997; 54:145-150.
21. Bayles K, Tomoeda C, Wood J, Montgomery E, Cruz R, Azuma T, McGeagh A. Change in cognitive function in idiopathic Parkinson's disease. Arch Neurol 1996; 53:1140-1146.
22. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol • 1997; 244:2-8. This is an excellent review of the current knowledge and understanding of cognitive deficits in Parkinson's disease.
23. Litvan I, Mega M, Cummings J, Fairbanks L, Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47:1184-1189.
24. Esmonde T, Giles E, Gibson M, Hodges J. Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy. J Neural 1996; 243:638-643.
25. Factor S, Friedman J. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12:483-496.
26. Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in Levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997; 12:610-612.
27. Gwinn K. Caviness J. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997; 12:119-121.
28. Sandor P, Lang A, Singal S, Angus C. Remoxipride in the treatment of levodopa-induced psychosis. J Clin Psychopharmacol 1996; 16:395-399.
29. Wolters E, Jansen E. Tuynman-Qua HG, Bergmans P. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47:1085-1087.
30. Beasley C, Tollefson G, Tran P. Safety of Olanzapine, J Clin Psychiatry 1997; 58 (suppl 10):13-17.
31. Schapira A. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov Disord 1994; 9:125-138.
32. Maurer I, Moller H. Inhibition of complex I by neuroleptics in normal human • brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 1997; 174:255-259. Half-maximal inhibition (IC50) of complex I of the mitochondrial respiratory chain was 0.1 mmol/l for haloperidol, 0.4 mmol/l for chlorpromazine and 0.5mmol/l for risperidone and zotepine, but 2.5 mmol/l (!) for clozapine.
33. Richard I, Kurlan R, Group TPS. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997; 49:1168-1170.
34. Soukup V, Ingram F, Schiess M, Bonnen J, Nauta H, Calverley J. Cognitive sequelae of unilateral posteroventral pallidotomy. Arch Neurol 1997; 54:947-950.
35. Tröster A, Fields J, Wilkinson S, Pahwa R, Miyawaki E, Lyons K, Koller W. Unilateral pallidal stimulation for Parkinson's disease: neurobehavioural functioning before and 3 months after electrode implantation. Neurology 1997; 49:1078-1083.